Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2021

Pharma News, 2021

Pfizer Asks FDA to Clear Covid Pill for High-Risk Patients
Pfizer Asks FDA to Clear Covid Pill for High-Risk Patients
Pfizer Inc. asked U.S. regulators for emergency-use authorization of its Covid-19 pill that could play a critical role in further protecting high-risk patients from the disease’s worst effects. ...
Rice lab first to mimic molecule found in poppies. Undergraduate leads synthesis of scarce extract, possible drug precursor
Rice lab first to mimic molecule found in poppies. Undergraduate leads synthesis of scarce extract, possible drug precursor
A Rice University undergraduate student’s grit and talent paid off in a big way when she introduced the first synthesis of a rare and potentially potent molecule drawn from poppies.  ...
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
NICE has issued a positive recommendation for Arvelle Therapeutics’ cenobamate (Ontozry), for the treatment of focal-onset seizures in adults with uncontrolled epilepsy in England and Wales. ...
FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatment
FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatment
The Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application to trehalose (SLS-005; Seelos Therapeutics, New York, NY) for spinocerebellar ataxia (SCA) treatme...
FDA Approves Treatment for Rare Blood Disease. Treatment is First FDA-Approved Option Patients Can Take Regardless of Previous Therapies
FDA Approves Treatment for Rare Blood Disease. Treatment is First FDA-Approved Option Patients Can Take Regardless of Previous Therapies
Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red...
Pfizer CEO calls those spreading vaccine misinformation 'criminals'
Pfizer CEO calls those spreading vaccine misinformation 'criminals'

"They have literally cost millions of lives,” Albert Bourla said in an interview with the Atlantic Council.

EU regulator backs COVID-19 drugs from Regeneron-Roche, Celltrion
EU regulator backs COVID-19 drugs from Regeneron-Roche, Celltrion
Europe's drug regulator has recommended two COVID-19 antibody therapies - one from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defe...
World Diabetes Day 2021
World Diabetes Day 2021
World Diabetes Day provides an opportunity to raise awareness of diabetes as a global public health issue and what needs to be done, collectively and individually, for better prevention, diagnosis...
Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try
Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try

Prexasertib has been on a more than two decade journey, and that doesn't include commercialization. 
EMA flags Johnson & Johnson COVID vaccine for rare disorder, passes mRNA shots for one side effect but probes another
EMA flags Johnson & Johnson COVID vaccine for rare disorder, passes mRNA shots for one side effect but probes another
Producers of adenovirus-vectored COVID-19 vaccines have had to deal with more questions about rare side effects than those making mRNA COVID-19 vaccines.
Organon to Acquire Forendo Pharma
Organon to Acquire Forendo Pharma
Organon, and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused ...
EC approves Valneva COVID-19 vaccine deal
EC approves Valneva COVID-19 vaccine deal
The European Commission (EC) has approved an agreement for Valneva to supply up to 60 million doses of the company’s inactivated COVID-19 vaccine candidate VLA2001 over a period of two years. ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand